Symbols / ELEV
ELEV Chart
About
No company description available for this symbol.
Fundamentals
Scroll to Statements| Sector | — | Industry | — | Market Cap | — |
| Enterprise Value | — | Income | — | Sales | — |
| Book/sh | — | Cash/sh | — | Dividend Yield | — |
| Payout | — | Employees | — | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | — | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | — |
| Current Ratio | — | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | — | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-05-15 07:00 | ROA | — |
| ROE | — | ROIC | — | Gross Margin | — |
| Oper. Margin | — | Profit Margin | — | Shs Outstand | — |
| Shs Float | — | Short Float | — | Short Ratio | — |
| Short Interest | — | 52W High | — | 52W Low | — |
| Beta | — | Avg Volume | — | Volume | — |
| Target Price | — | Recom | — | Prev Close | — |
| Price | — | Change | — |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
—
Latest analyst target
3. DCF / Fair value
—
Simplified FCF or EPS-based estimate
Ratings
No analyst ratings or price targets available.
- Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right - PR Newswire Mon, 09 Jun 2025 07
- Elevation Oncology completes merger with Concentra Biosciences, delists from Nasdaq - Investing.com Wed, 23 Jul 2025 07
- Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates - PR Newswire hu, 15 May 2025 07
- Elevation Oncology agrees to be acquired by Concentra - The Pharma Letter ue, 10 Jun 2025 07
- Elevation Oncology Completes Merger with Concentra Biosciences - TipRanks Wed, 23 Jul 2025 07
- Elevation is latest biotech to face activist investor demands to wind down - Fierce Biotech hu, 17 Apr 2025 07
- Elevation Oncology Plunges 42% on Ending Development of Lead Drug - Zacks Investment Research Fri, 21 Mar 2025 07
- Elevation Oncology (ELEV) Downgraded by William Blair Following Acquisition Announcement | ELEV Stock News - GuruFocus Mon, 09 Jun 2025 07
- Why Elevation Oncology (ELEV) Is Among the Best Penny Stocks to Invest In According to Media? - Yahoo Finance ue, 07 Jan 2025 08
- Elevation Oncology agrees to Concentra Biosciences buyout By Investing.com - Investing.com Nigeria Sat, 06 Sep 2025 07
- Up 825% So Far in 2024, Can This Penny Stock Go Any Higher? - Nasdaq Wed, 27 Mar 2024 07
- Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements - PR Newswire hu, 06 Mar 2025 08
- Elevation Oncology ends license agreement with CSPC Megalith Biopharmaceutical - Investing.com Wed, 02 Jul 2025 07
- Empery Asset Management's Strategic Acquisition in Elevation Oncology - Yahoo Finance Wed, 09 Oct 2024 07
- Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones - PR Newswire Mon, 13 Jan 2025 08
Insider Transactions
No recent insider transactions.
Financials
No financial statements available. Data is sourced from Yahoo Finance and cached; historical storage may be added later.
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for ELEV
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|